{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:43Z","timestamp":1784700403056,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cardiac amyloidosis (CA) has been considered a rare disease. However, its prevalence is growing as healthcare practitioners have new, less invasive diagnostic tools that aid in the early detection of this disease. Bone scintigraphy with monoclonal protein testing is one such evidence-based, noninvasive screening option that can be offered in community healthcare facilities. This work aims to identify intervention strategies to improve the timely workup of transthyretin CA, including evidence-based practices such as bone scintigraphy and monoclonal protein testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The team used rapid qualitative content analysis to develop a system map of care for cardiac amyloidosis, guided by both patient and healthcare expert perspectives. To explore the map's utility and accuracy, the team conducted follow-up in-depth interviews with clinicians. They explored clinicians' perspectives on strategies to facilitate the early diagnosis of CA and explored barriers and implementation strategies that can influence the diagnostic work-up for CA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinicians provided recommendations for how to expand the map, particularly in terms of including additional healthcare professionals, screening strategies, and barriers to care for patients. After expanding the preliminary system map of care, the team identified 23 distinct strategies to improve the early detection of CA. Clinicians recommended additional strategies, such as patient and provider education, patient take-back, the use of artificial intelligence with electronic health record data, and the formation of healthcare teams specializing in cardiac amyloidosis, to enhance early detection and treatment of this condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This work can inform researchers and clinicians about selecting and implementing intervention and implementation strategies within health systems to enhance the early detection of cardiac amyloidosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1810173","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:53:35Z","timestamp":1784699615000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying implementation strategies to increase the early detection of cardiac amyloidosis: a pre-implementation study"],"prefix":"10.3389","volume":"13","author":[{"given":"Alexis M.","family":"Koskan","sequence":"first","affiliation":[{"name":"College of Health Solutions, Arizona State University","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenice","family":"Guzman-Clark","sequence":"additional","affiliation":[{"name":"Southern Arizona VA Health Care System","place":["Tucson, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry L.","family":"Ball","sequence":"additional","affiliation":[{"name":"Research Service Line, VA Northeast Ohio Healthcare System","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Renger","sequence":"additional","affiliation":[{"name":"JUST Evaluation Services","place":["Tucson, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh","family":"Dev","sequence":"additional","affiliation":[{"name":"College of Health Solutions, Arizona State University","place":["Phoenix, AZ, United States"]},{"name":"Southern Arizona VA Health Care System","place":["Tucson, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.118.037417","article-title":"Protein misfolding in cardiac disease","volume":"139","author":"Hofmann","year":"2019","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-020-00738-8","article-title":"Advances in the treatment of cardiac amyloidosis","volume":"21","author":"Macedo","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/biomedicines10071566","article-title":"Re-definition of the epidemiology of cardiac amyloidosis","volume":"10","author":"Rossi","year":"2022","journal-title":"Biomedicines"},{"key":"B4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1056\/NEJMc1814074","article-title":"Tafamidis for transthyretin amyloid cardiomyopathy","volume":"380","author":"Manion","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0735-1097(23)01103-8","article-title":"Incidence and temporal trends of transthyretin cardiac amyloidosis in a national sample of veterans with heart failure","volume":"81","author":"Dev","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40959-024-00282-6","article-title":"Increasing clinicians\u2019 suspicion of ATTR amyloidosis using a retrospective algorithm","volume":"10","author":"Ammon","year":"2024","journal-title":"Cardio Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1035719X1501500403","article-title":"System evaluation theory (SET): a practical framework for evaluators to meet the challenges of system evaluation","volume":"15","author":"Renger","year":"2015","journal-title":"Eval J Australas"},{"key":"B12","first-page":"e0339063","article-title":"Testing the utility of the first step of system evaluation theory in creating a system map of care for cardiac amyloidosis early detection: A case study","volume-title":"PLOS One","author":"Ball","year":"2026"},{"key":"B13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1177\/104973230201200611","article-title":"Matrix analysis as a complementary analytic strategy in qualitative inquiry","volume":"12","author":"Averill","year":"2002","journal-title":"Qual Health Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13012-015-0209-1","article-title":"A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project","volume":"10","author":"Powell","year":"2015","journal-title":"Implement Sci"},{"key":"B15","year":"2023"},{"key":"B16","year":"2016"},{"key":"B17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ejhf.2823","article-title":"Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study","volume":"25","author":"Tini","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00380-024-02408-3","article-title":"Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years","volume":"39","author":"Achten","year":"2024","journal-title":"Heart Vessels"},{"key":"B19","doi-asserted-by":"publisher","first-page":"oeac011","DOI":"10.1093\/ehjopen\/oeac011","article-title":"Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience","volume":"2","author":"Brons","year":"2022","journal-title":"Eur Heart J Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"33S","DOI":"10.1378\/chest.118.2_suppl.33S","article-title":"Provider education to promote implementation of clinical practice guidelines","volume":"118","author":"Ockene","year":"2000","journal-title":"Chest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13012-016-0393-7","article-title":"Tailoring implementation strategies for evidence-based recommendations using computerised clinical decision support systems: protocol for the development of the GUIDES tools","volume":"11","author":"Van de Velde","year":"2015","journal-title":"Implement Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s11606-021-07158-w","article-title":"Care coordination models and tools\u2014systematic review and key informant interviews","volume":"37","author":"Duan-Porter","year":"2022","journal-title":"J Gen Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.14797\/mdcvj.1071","article-title":"Future directions in cardiac amyloidosis","volume":"18","author":"Trachtenberg","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patient experience survey from the amyloidosis research consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcjq.2020.02.004","article-title":"Health care provider factors associated with patient-reported adverse events and harm","volume":"46","author":"Giardina","year":"2020","journal-title":"Joint Comm J Qual Patient Saf"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3390\/jcm9051334","article-title":"Machine learning enables prediction of cardiac amyloidosis by routine laboratory parameters: a proof-of-concept study","volume":"9","author":"Agibetov","year":"2020","journal-title":"J Clin Med"},{"key":"B27","article-title":"Mayo Clinic Proceedings","author":"Grogan","year":"2021"},{"key":"B28","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamacardio.2021.6059","article-title":"High-throughput precision phenotyping of left ventricular hypertrophy with cardiovascular deep learning","volume":"7","author":"Duffy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/jpm11121268","article-title":"Convolutional neural networks for fully automated diagnosis of cardiac amyloidosis by cardiac magnetic resonance imaging","volume":"11","author":"Agibetov","year":"2021","journal-title":"J Pers Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/ehjdh\/ztae022","article-title":"The prognostic value of artificial intelligence to predict cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"5","author":"Pereyra Pietri","year":"2024","journal-title":"Eur Heart J Digit Health"},{"key":"B31","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00259-024-06922-4","article-title":"Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis","volume":"52","author":"Shiri","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.3390\/jcm15083037","article-title":"Artificial intelligence in cardiac amyloidosis: a state-of-the-art review","volume":"15","author":"Bukhari","year":"2026","journal-title":"J Clin Med"},{"key":"B33","year":"2012"},{"key":"B34","article-title":"Evolution of the heart team: Advances in care delivery after 2 decades of TAVR. Cardiology Today","author":"Schaffer","year":"2022"},{"key":"B35","first-page":"303","article-title":"A collaborative approach to amyloidosis and a multidisciplinary care framework\u2013position statement from the international society of amyloidosis","volume-title":"Amyloid","author":"Sanchorawala","year":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"ACC Expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","article-title":"Assessment of patients with hereditary transthyretin amyloidosis\u2013understanding the impact of management and disease progression","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"B38","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamacardio.2021.0835","article-title":"Transthyretin genetic testing","volume":"6","author":"Sinha","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"ehag222","DOI":"10.1093\/eurheartj\/ehag222","article-title":"Cascade genetic screening in families with hereditary transthyretin amyloidosis: diagnostic and prognostic impact","author":"Cappelli","year":"2026","journal-title":"Eur Heart J"},{"key":"B40","first-page":"4","article-title":"Cardiac amyloidosis: a comprehensive clinical resource for cardiovascular nurses","volume":"33","author":"Groenewegen-Beukeboom","year":"2023","journal-title":"Can J Cardiovasc Nurs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ejhf.3339","article-title":"Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis","volume":"26","author":"Muller","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B43","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.cjca.2019.12.034","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jhsa.2019.06.016","article-title":"Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis","volume":"44","author":"Donnelly","year":"2019","journal-title":"J Hand Surg Am"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"B46","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/dc.20131","article-title":"Improved detection of amyloid in fat pad aspiration: an evaluation of Congo red stain by fluorescent microscopy","volume":"31","author":"Giorgadze","year":"2004","journal-title":"Diagn Cytopathol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/87564793211018680","article-title":"Quality improvement initiatives in sonography education: a review of the literature","volume":"37","author":"Sorrentino","year":"2021","journal-title":"J Diagn Med Sonogr"},{"key":"B48","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2\u2014diagnostic criteria and appropriate utilization","volume":"27","author":"Dorbala","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13244-018-0599-0","article-title":"Added value of double Reading in diagnostic radiology, a systematic review","volume":"9","author":"Geijer","year":"2018","journal-title":"Insights Imaging"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e057127","DOI":"10.1136\/bmjopen-2021-057127","article-title":"Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis\u2014implications for public health communications in Australia","volume":"12","author":"Enticott","year":"2022","journal-title":"BMJ open"},{"key":"B51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/1035719X211066961","article-title":"Lessons learned in evaluating system interdependencies using qualitative methods","volume":"22","author":"Souvannasacd","year":"2022","journal-title":"Eval J Australas"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1810173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:53:38Z","timestamp":1784699618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1810173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":51,"alternative-id":["10.3389\/fcvm.2026.1810173"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1810173","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1810173"}}